Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

A Study to Assess New Formulations of TEV-56286

brain-icon.png
Condition(s):
Healthy Participants
Status:
Completed
Requirements:
18 years to 60 Years
Interventions:
Drug: TEV-56286 Test | Drug: TEV-56286 Reference
Learn more The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

Effect of a 5-Day Regimen on Peripheral Stem Cell Mobilization

disease-icon.png
Condition(s):
Healthy Participants
Status:
Terminated
Requirements:
18 Years to 60 Years
Interventions:
Drug: Tbo-filgrastim
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Mass Balance Clinical Trial With TEV-56286

brain-icon.png
Condition(s):
Healthy Participants
Status:
Completed
Requirements:
18 Years to 65 Years
Interventions:
Drug: TEV-56286; [14C]-TEV-56286
Learn more Primary objectives: To investigate the mass balance and excretion of TEV-56286 following a single oral dose of [14C]-TEV-56286 To assess the pharmacokinetics following a single oral dose of [14C]-TEV-56286 Secondary objective: To evaluate the safety and tolerability of TEV-56286 following once daily multiple oral dose administration The total duration of the clinical trial for each participant is expected to be approximately 59 days.